Interaction of LDL and platelets in ischaemic and ischaemic risk subjects

Indian Journal of Clinical Biochemistry

Volumn 20, Issue 1, 2005, Pages 87-94

  Gupta, Yashika ^b   Mallika, V ^a   Srivastava, D K ^a  

^a G B PANT HOSPITAL   (India)

^b NONE   (United States)

Author keywords

Calcium; LDL; ox LDL; Platelet; Platelet aggregation

Indexed keywords

ADENOSINE DIPHOSPHATE; CALCIMYCIN; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NIFEDIPINE; OXIDIZED LOW DENSITY LIPOPROTEIN; PROTEIN KINASE INHIBITOR; STAUROSPORINE; THROMBIN; THROMBOCYTE ACTIVATING FACTOR; THROMBOCYTE RECEPTOR; TRIACYLGLYCEROL; VERAPAMIL;

ARTICLE; ATHEROSCLEROSIS; CAUSE OF DEATH; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITY GRADIENT CENTRIFUGATION; HUMAN; HUMAN CELL; HYPERLIPIDEMIA; IN VITRO STUDY; ISCHEMIC HEART DISEASE; LIPID COMPOSITION; SECOND MESSENGER; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOSIS;

EID: 14944385645     PISSN: 09701915     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02893049     Document Type: Article

References (42)

1. Ardlie, N.G., Selley, M.L. and Simons, L.A. (1989). Platelet activation by oxidatively modified low density lipoproteine. Atherosclerosis 76, 117-124.
2. Surya, I.I., Gorter, G., Mommersteeg, M. and Akkerman, J.W.N. (1992). Enhancement of platelet functions by low density lipoproteins. Biochim. Biophys. Acta 1165, 19-26.
3. 2+ concentration and dense tubular system in human platelets. Thromb. Res. 72, 33-37.
4. van Willigen, G., Gorter, G. and Ackerman, J.W. (1994). LDLs increase the exposure of Fibrinogen binding sites on platelets and secretion of dense granules. Atheroscler Thrombo. 14, 41-46.
5. Andrews, H.E., Aitken, J.W., Hassall, D.G., Skinner, V.O. and Bruckdorfer, K.R. (1987). Intracellular mechanisms in the activation of human platelets by low-density iipoproteins. Biochem. J. 242, 559-564.
6. Dunn, R.C., Schachter, M., Miles, C.M.M., Feher, M.D., Tranter, P.R., Bruckdorfer, K.R. and Sever, P.S. (1988). Low density lipoproteins increase intracellular calcium in aequorin-loaded platelets. FEBS Lett. 238, 357-360.
7. Witztum, J.L. and Steinberg, D. (1991). Role of oxidized low density lipoprotein in atherogenesis. J. Clin. Invest. 88, 1785-1792.
8. Berliner, J.A., Navab, M., Fogelman, A.M., Frank, J.S., Demer, L.L., Edwards, P.A., Watson, A.D. and Lasis, A.J. (1995). Atherosclerosis: basic mechanisms, oxidation, inflammation and genetics. Circulation 91, 2488-2498.
9. Aviram, M., Deckelbaum, R. and Brook, J.G. (1985). Platelet function in a case with abetalipoproteinemia. Atherosclerosis 57, 313-323.
10. Block, L.H., Knorr, M., Vogt, E., Locher, R., Vetter, W., Groscurth, P., Qiao, B.Y., Pometta, D., James, R., Rigenass, M. and Fleischer, A. (1988). Low density lipoproteine cause general cellular activation with increased phosphatidylinositol turnover and lipoprotein catabolism. Proc. Natl. Acad. Sci. USA 85, 885-889.
11. Knorr, M., Locher, R., Vogt, E., Vetter, W., Block, L.H., Ferracin, F., Lefkovits, H. and Pletscher, A. (1988). Rapid activation of human platelets by low concentrations of low-density lipoprotein via phosphatidylinositol cycle. Eur. J. Biochem. 172, 753-759.
12. Prisco, D., Rogasi, P.G., Paniccia, R., Coppo, M., Abbate, R., Gensini, G.F. and Neri Semeri, G.G. (1988). Altered lipid combosition and thromboxane A2 formation in platelets from patients affected by IIa hyperlipoproteinemia. Thromb. Res. 50, 593-604.
13. Pedreno, J., de Castellarnau, Cullare, C., Sanchez, J., Gomez-Gerique, J., Ordonez-Llanos, J. and Gonzales-Sastre, F. (1992). LDL binding sites on platelets differ from the "classical" receptor of nucleated cells. Arterioscler. Thromb. 12, 1353-1362.
14. Bumstein, M., Scolnick, H.R. and Morfin, R. (1970). Rapid method for the isolation of lipoproteins from human serum by precipitation with polyamines. J. Lipid Res. 2, 583-595.
15. Chung, B.H., Wilkinson, T., Geer, J.L. and Segrest, J.P. (1986). Preparative and quantitative isolation of plasma lipoproteins: rapid single discontinuous density gradient ultracentrifugation in a vertical rotor. J. Lipid Res. 21, 284-291.
16. Johnson, P.C., Ware, J.A. and Salzman, E.W. (1985). Concurrent measurement of platelet ionized calcium concentration and aggregation. Studies with the lumi-aggregometer. Thromb. Res. 40, 435-443.
17. Born, G.V.R. (1962). Quantitative investigations into the aggregation of blood platelets. J. Physiol. 162, 67-71.
18. Salky, N. and Pugdale, M. (1973). Platelet abnormalities in ischemic heart disease. Am. J. Cardiol. 32, 612-617.
19. Aviram, M. and Brook, J.G. (1982). The effect of human plasma on platelet function in familial hypercholesterolemia. Thromb. Res. 26, 101-109.
20. Malle, E., Cries, A., Kosiner, G.M., Pfeiffer, K., Nimpf, J. and Hermetter, A. (1989). Is there any correlation between platelet aggregation, plasma lipoporteins, apoproteins and membrane fluidity of human blood platelets. Thromb. Res. 53, 181-190.
21. Lam, J.Y.T., Latour, J.G., Lesperance, J. and Waters, D. (1994). Platelet aggregation, coronary artery disease progression and future coronary events. Am. J. Cardiol. 73, 333-338.
22. Carvalho, A.C.A., Colman, R.W. and Lees, R.S. (1974). Platelet function in hypertipoproteinemia. N. Engl. J. Med. 290, 434-438.
23. Braquet, P., Touqui, J., Shen, T.Y. and Vargaftig, B.B. (1987). Perspectives in platelet-activating factor research. Pharmacol. Rev. 39, 97-145.
24. Braquet, P., Paubert-Braquet, M., Koltai, M., Bourgain, R., Busolino, F. and Hosford, D. (1989). Is there a case for PAF antagonists in the treatment of ischemic states? Trends Pharmacol. Sci. 10, 23-30.
25. Koltai, M., Tosaki, A., Hosford, D. and Braquet, P. (1989). Ginkgolide B protects isolated hearts against arrhythmias induced by ischemia but not reperfusion. Eur. J. Pharmacol. 164, 293-302.
26. Guillon, J.M., Thievant, P., Koltai, M., Pirotzky, E. and Braquet, P. (1989). Antiarrhythimic effect of a specific PAF autagonist (BNS2021) on ischemia-reperfusion in the dog. J. Mol. Cell Card. 21, S141.
27. Marcus, A.J., Safier, L.B., Ullman, H.L., Wong, K.T.H., Broekman, M.J., Weksler, B.B. and Kaplan, K. (1981). Effects of acetyl glyceryl ether phosphoryl choline on human platlet function in vitro. Blood 58, 1027-1031.
28. Carolyn, M.C., Pifer, D., Byers, L.W. and Muirhead, E.E. (1982). Effect of platelet activating factor (PAF) on human platelets. Blood 59, 582-585.
29. Beaumont, D.O., Whitten, K.W., Mock, R.G. and Slattery, C.W. (1989). Measuring platelet function with platelet shape change, an early event in aggregation. Thromb. Res. 53, 109-127.
30. Han, P., Boat Wright, C. and Ardlie, N.G. (1982). Inhibition of platelet function by antiarrhythmic drugs, verapamil and disopyramide. Thromb. Haemostas. 47, 150-153.
31. Han, P., Boat Wright, C. and Ardlie, N.G. (1983). Effect of the calcium-entry blocking agent nifedipine on activation of human platelets and comparison with verapamil. Thromb. Haemostas. 50, 513-517.
32. Onoda, J.M., Sloane, B.F. and Honn, K.V. (1984). Antithrombogenic effects of calcium channel blockers: synergism with prostacyclin and thromboxane synthesis inhibitors. Thromb. Res. 34, 367-378.
33. 2+ uptake in human blood platelets. Am. J. Physiol. 239, H 483-H 488.
34. 2+ mobilization in blood platelets as visualized by chloretetracycline fluorescence. Am. J. Physiol. 241, H 613-H 619.
35. Dandona, P., Thusu, K., Khurana, U., Love, J., Aljada, A. and Mousa, S. (1996). Calcium, calmodulin and protein kinase C dependence of platelet shape change. Thromb. Res. 81, 163-175.
36. Oda, A., Yokoyama, K., Murata, M., Tokuhira, M., Nakamura, K., Handa, M., Watanabe, K. and Ikeda, Y. (1995). Protein tyrosine phosphorylation in human platelets during shear stress-induced platelet aggregation (SIPA) is regulated by glycoprotein (GP) IB/IX as well as GPIIb/IIIa and requires infact cytoskeleton and endogenous ADP. Thromb. Haemost. 74, 736-741.
37. Kowalska, M.A., Tuszynski, G.P. and Capuzzi, D.M. (1990). Plasma lipoproteins mediate platelet adhesion. Biochem. Biophys. Res. Commun. 172, 113-118.
38. Katzman, P.L., Bose, R., Walker, S., Perry, Y. and Bolli, P. (1991). Temperature-dependence of LDL binding and activation of human platelets. Thromb. Res. 64, 503-508.
39. Katzman, P.L., Bose, R., Henry, S., Mclean, D.L., Walker, S., Fyfe, C., Perry, Y., Mymin, and Bolli, P. (1994). Serum lipid profile determines platelet reactivity to native and modified LDL-cholesterol in humans. Thromb. Haemost. 71, 627-632.
40. Gupta, Y. Mallika, M and Srivastava, D.K. (2003). Kinetic analysis of LDL oxidation in IHD and IHD risk subjects in India population. Ind. J. Clin. Biochem. 18, 35-45.
41. Esterbauer, H., Dieber-Rothender, M., Waeg, G., Puhl, H. and Tatzber, F. (1990). Biochemical, structural and functional properties of oxidized low density lipoprotein. Biochem. Soc. Trans. 18, 1059-1061.
42. Kalant, N. and McCormick, S. (1992). Inhibition by serum components of oxidation and collagen-binding of low density lipoprotein. Biochim. Biophys. Acta 1128, 211-219.